Effect of carbogen to chemoradiation in volume of rectal cancer

Christina Hari Nawangsih, Soehartati Gondhowiardjo, Sofia Mubarika Haryana, Soeharyo Hadisaputro, Catharina Suharti, Edi Dharmana, Hermina Sukmaningtyas, Fifin Luthfia Rahmi, Ignatius Riwanto

Research output: Contribution to journalArticlepeer-review


The outcome of inoperable rectal cancer treatment by chemotherapy, radiotherapy, and targeted therapy are still unfavorable. Carbogen is a combination of 98% oxygen and 2% carbon dioxide proven effective as chemoradiosensitizer. The aim of this study is to know the effect of concurrent carbogen and chemoradiotherapy in locally advanced rectal cancer by measuring the shrinkage of the tumor volume. The design of this study was randomized true experimental 2 groups pre and post-test-controlled design. Samples were patients with locally advanced rectal cancer. MRI of the pelvis before and 4-8 weeks after the chemoradiation were examined. A total of 28 subjects were randomized to 14 patients who received concurrent chemoradiation with carbogen (treatment group) and 14 patients chemoradiation (control) The tumor shrinkage in the treatment group (13.08 to 6.08 cm3) was significantly higher compared to the control group (18.00 to 12.83 cm3). Supplementation of carbogen to standard treatment chemoradiation for locally advanced rectal cancer significantly shrinkage the tumor volume.

Original languageEnglish
Pages (from-to)15-20
Number of pages6
JournalActa Medica Iranica
Issue number1
Publication statusPublished - 1 Jan 2020


  • Carbogen
  • Chemoradiation
  • Rectal cancer
  • Volume


Dive into the research topics of 'Effect of carbogen to chemoradiation in volume of rectal cancer'. Together they form a unique fingerprint.

Cite this